pSivida initiates posterior uveitis trial
pSivida (ASX:PVA) has commenced a US phase III trial of its ocular insert for the treatment of posterior uveitis.
The first three US clinical sites have started recruiting patients for the study, which is one of two US trials planned to accompany a New Drug Application with the US FDA.
pSivida said the trials are expected to involve around 15 sites in the US and additional clinical sites worldwide.
The ocular micro-insert is the same as the design pSivida has licensed to Alimera Sciences for diabetic macular edema (DME) treatment Iluvien. Alimera has secured marketing approval for the product in six European countries, but is still awaiting approval in the US.
pSivida has received permission from the FDA to cite data from Alimera’s trials in its own FDA application for its posterior uveitis treatment.
The insert also delivers the same drug used in Retisert, pSivida’s existing FDA-approved posterior uveitis treatment.
“In our uveitis trials, we expect to maintain similar efficacy to that seen in the Retisert phase III trials but with a similar [low] side effect profile to that seen in DME patients in the phase III studies for Iluvien,” pSivida CEO Dr Paul Ashton said.
Another advantage the micro-insert has over Retisert is that it can be injected during an office visit, rather than implanted through a surgical procedure, he added.
pSivida shares were trading 2.69% higher at $4.20 as of around 1 pm on Wednesday.
RSV immunisation program for babies slashes hospital stays
An Australian-first study has demonstrated the effectiveness of immunisation against respiratory...
A targeted treatment option for psoriasis
New research from MedUni Vienna paves the way for the development of a therapy that not only...
Maternal cannabis use puts kids at risk of behavioural problems
Children exposed to their mother's cannabis use during pregnancy and after birth are three...